Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09ADT
|
|||
| Former ID |
DNC000130
|
|||
| Drug Name |
ABT-418
|
|||
| Synonyms |
Abt-418; Abt 418; 147402-53-7; 3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole; CHEMBL274525; (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole; (S)-3-methyl-5-(1-methylpyrrolidin-2-yl)isoxazole; C9H14N2O; Isoxazole, 3-methyl-5-((2S)-1-methyl-2-pyrrolidinyl)-; Isoxazole, 3-methyl-5-(1-methyl-2-pyrrolidinyl)-, (S)-; Isoxazole, 3-methyl-5-[(2S)-1-methyl-2-pyrrolidinyl]-; 3-methyl-5-[(2S)-1-methylpyrrolidin-2-yl]-1,2-oxazole; AC1L3OPH; SCHEMBL194161; DTXSID10163711; ILLGYRJAYAAAEW-QMMMGPOBSA-N; ZINC3786099; BDBM50035398
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Discontinued in Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C9H14N2O
|
|||
| Canonical SMILES |
CC1=NOC(=C1)C2CCCN2C
|
|||
| InChI |
1S/C9H14N2O/c1-7-6-9(12-10-7)8-4-3-5-11(8)2/h6,8H,3-5H2,1-2H3/t8-/m0/s1
|
|||
| InChIKey |
ILLGYRJAYAAAEW-QMMMGPOBSA-N
|
|||
| CAS Number |
CAS 147402-53-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neuronal acetylcholine receptor alpha-4 (CHRNA4) | Target Info | Agonist | [2] |
| Neuronal acetylcholine receptor beta-2 (CHRNB2) | Target Info | Agonist | [2], [3] | |
| Nicotinic acetylcholine receptor (nAChR) | Target Info | Agonist | [4] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Cholinergic synapse | ||||
| Nicotine addiction | ||||
| Panther Pathway | Nicotinic acetylcholine receptor signaling pathway | |||
| Nicotine pharmacodynamics pathway | ||||
| Reactome | Highly sodium permeable acetylcholine nicotinic receptors | |||
| Highly calcium permeable postsynaptic nicotinic acetylcholine receptors | ||||
| Highly calcium permeable nicotinic acetylcholine receptors | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | ||||
| Nicotine Activity on Dopaminergic Neurons | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004036) | |||
| REF 2 | (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization. J Pharmacol Exp Ther. 1994 Jul;270(1):319-28. | |||
| REF 3 | Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch Med Res. 2000 Mar-Apr;31(2):131-44. | |||
| REF 4 | Enhancement of sustained attention performance by the nicotinic acetylcholine receptor agonist ABT-418 in intact but not basal forebrain-lesioned rats. Psychopharmacology (Berl). 1999 May;144(2):175-82. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.